Streetbeat News

CHE

Chemed Corporation

https://www.chemed.com

Industry

Medical - Care Facilities

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Open

564.22

Mkt cap

8.4B

Volume

88K

High

565.81

P/E Ratio

28.22

52-wk high

654.62

Low

556.15

Div yield

0.00

52-wk low

523.33

Chemed Corporation has raised its FY24 EPS guidance from $23.30-$23.70 to $23.55-$23.80, surpassing the $23.21 estimate. VITAS is expected to see significant revenue and ADC growth, while Roto-Rooter is forecasted to experience a revenue decline. Covenant Health is projected to contribute positively to VITAS' revenue.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 8:19 pm

Chemed (NYSE:CHE) reported Q2 earnings of $5.47 per share, missing the analyst estimate of $5.59. Sales were $595.88M, also below the $599.19M estimate. Despite the misses, earnings and sales increased year-over-year by 34.07% and 7.60%, respectively.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 8:17 pm

Chemed (NYSE:CHE) has significantly outperformed the market over the past 15 years, delivering an average annual return of 18.98%. A $1000 investment in CHE 15 years ago would be worth $13,515.05 today. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

July 15, 2024 | 5:00 pm

Chemed's (NYSE:CHE) short interest has risen by 15.52%, with 350,000 shares sold short, representing 2.68% of its float. This increase in short interest could indicate bearish sentiment among investors. However, Chemed's short interest is still lower than the peer group average of 10.76%.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 2:45 pm

RBC Capital analyst Ben Hendrix maintains an Outperform rating on Chemed (NYSE:CHE) but lowers the price target from $712 to $697.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 2:56 pm

Chemed's (NYSE:CHE) short interest has decreased by 4.97%, with 451 thousand shares sold short, representing 3.44% of its float. This decline in short interest, compared to the peer group average of 10.10%, suggests a more bullish sentiment towards CHE. The coverage time for short positions is 6.59 days based on trading volume.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 4:00 pm

Chemed shares are trading lower following the announcement of Q1 financial results that did not meet expectations.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 1:11 pm

Chemed (NYSE:CHE) reported Q1 adjusted earnings of $5.20 per share, missing the consensus estimate of $5.48, and sales of $589.23M, also below the estimate of $591.46M. Despite these misses, both earnings and sales showed an increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 8:20 pm

VITAS Healthcare, a subsidiary of Chemed Corporation (NYSE:CHE), has agreed to acquire hospice operations and an assisted living facility from Covenant Care for $85 million. The operations are located across Florida and Alabama. The acquisition, aimed at expanding VITAS's service footprint, is expected to close in Q2 2024, pending regulatory approvals. This move is seen as a strategic expansion, enhancing VITAS's presence in key markets and continuing its mission of providing high-quality, patient-centered care.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 1:12 pm

Chemed (NYSE:CHE) has seen its short percent of float increase by 3.02% since the last report, with 441 thousand shares sold short, representing 3.41% of available shares. This indicates a bearish sentiment among investors, although it's not a definitive predictor of stock movement. Chemed's short interest is below its peer group average of 10.07%, suggesting less bearish sentiment compared to its peers.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 5:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.